Rapport Therapeutics, Inc.
RAP-219
bipolar mania
Resolved
77days ago
Phase 2 readout · Apr 21, 2026
What's at stake
Phase 2 trial results for RAP-219 in bipolar mania are due Apr 21, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Outside of FOS, Rapport is conducting a Phase 2 trial evaluating RAP-219 in bipolar mania, with topline results expected in the first half of 2027,”